NICE backs Lilly’s Emgality for migraine, adding pressure on...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve th

CHMP turns down Lilly’s Emgality for cluster headache

Lilly firms up case for Emgality in migraine market chase

Lilly dips as biomed chief Christi Shaw heads to Gilead

Lilly's migraine drug gets key cluster headache approval

The FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving the calcitonin gene-related peptide (CGRP) antibody a key poin

Lilly claims fast FDA review for Emgality in cluster headach...

Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache.<